Influenza Vaccine Effectiveness in Europe

2009 - en cours

Mots-clés : Epidémiologie, Grippe, Vaccin, Efficacité

mise à jour : 16 août 2013

Présentation
I-Move is a multicentre case-control study based on sentinel practitioner surveillance networks from seven European

countries was undertaken to estimate the effectiveness of 2009–2010 pandemic and seasonal influenza vaccines against medically attended influenza-like illness (ILI) laboratory-confirmed as pandemic influenza A (H1N1) (pH1N1).

Sentinel practitioners swabbed ILI patients using systematic sampling. We included in the study

patients meeting the European ILI case definition with onset of symptoms less than 14 days after the start of national vaccination campaigns. We compared influenza cases to influenza laboratory-negative controls. A valid vaccination

corresponded to less than 14 days between receiving a dose of vaccine and symptom onset. We estimated pooled vaccine effectiveness (VE) as 1 minus the odds ratio with the study site as a fixed effect. Using logistic regression, we adjusted VE for potential confounding factors (age group, sex, month of onset, chronic diseases and related hospitalizations, smoking history, seasonal influenza vaccinations, practitioner visits in previous year). We conducted a complete case analysis excluding individuals with missing values and a multiple multivariate imputation to estimate missing values.

Apport d'Open Rome
Open Rome est responsable du volet français de l'étude utilisant la méthode du « Test Negative Design ».

Par ailleurs, Open Rome a mené au sein du groupe d'étude I-Move une étude originale comparant les résultats obtenus selon qu'on tire ou non au sort les cas et les témoins.

Partenaires
Réseau des GROG
ECDC
EpiConcept

Financement
Le projet Européen I-Move a été financé par le ECDC (European Center for Disease prevention and Control). En 2012 et 2013, la baisse puis la suppression du financement public a conduit les participants à travailler bénévolement.

Responsables
Dr Bruno CIANCIO, ECDC
Dr Alain MOREN, médecin épidémiologiste, EpiConcept
Dr Marta VALENCIANO, médecin épidémiologiste, EpiConcept

Documents téléchargeables

Contacts
Marie FORESTIER mforest@openrome.org. Tél : +33.1.56.55.51.64